CAR-T cells for low-risk relapsed hodgkin lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new treatment using special immune cells (CAR-T cells) that are designed to find and attack lymphoma cells in people whose Hodgkin lymphoma has come back but is considered low risk. The study aims to see if this treatment works well and is safe for patients who have already responded to a first round of re-treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 6 and 29 years old.
- You have been diagnosed with CD30+ classical Hodgkin lymphoma (a type of lymphoma that has relapsed after treatment).
- You have had a biopsy confirming the lymphoma is CD30+ and that it is low risk according to the study's criteria (e.g., stage IA or IIA at diagnosis, with remission lasting at least a year).
- Your cancer responds well to your first re-treatment (reinduction) therapy.
- You are willing to use effective contraception if you are of childbearing age.
- You are willing to follow the study procedures and are able to give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy (CD30 CAR T-cells) given after a stem cell transplant to treat Hodgkin lymphoma that has not responded well. It may help your body's immune cells fight the cancer more effectively.
This Phase 1 trial tests a new immune therapy made from your own immune cells (CAR T cells) for relapsed or refractory Hodgkin or non-Hodgkin lymphoma that has CD30 on the tumor. It aims to see if the treatment can shrink the lymphoma and find the safest dose.
This trial tests a new treatment using your own immune cells, called CAR-T cells, that are modified to find and attack lymphoma cells with CD20 or CD30 markers. It is for people whose lymphoma has not responded to standard treatments or has returned after treatment.
This trial tests a personalized treatment using your own immune cells (called CAR-T cells) that are modified in a lab to target and kill lymphoma cells. It is for people with a type of B-cell non-Hodgkin lymphoma that has come back or not improved after standard treatments.
This trial tests a lab-made immune therapy (CAR T cells) for lymphoma that has come back or did not respond to treatment, specifically CD30-positive T-cell lymphoma. The goal is to shrink the cancer and help keep it under control after previous therapies, including people who have relapsed after stem cell transplant.
This study tests a new kind of CAR-T cell therapy for people with certain types of B-cell lymphoma that have come back or not improved after standard treatments. The CAR-T cells have been modified to turn off two genes (BCOR and ZC3H12) to make them work better against the cancer.
Hear when a new Classical Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.